September 26-27, 2024 | Hyatt Regency, New Brunswick, NJ

Frank Chrzanowski, Ph.D.

Frank Chrzanowski is a semi-retired Pharmaceutical Scientist with over 40 years’ experience in the development of Pharmaceuticals. His experience includes 20 years supporting solid dosage form development heading the Preformulation / Physical Pharmacy Laboratories at McNeil Pharmaceutical and the RW Johnson Pharmaceutical Research Institute, and over 20 years as a Consultant and Expert/Expert Witness

The Preformulation Laboratories provided support primarily to the Solid Dosage Form Development efforts, as well as Medicinal and Development Chemistry, Pharmacology, Drug Metabolism and Manufacturing. It was also responsible for the development of liquid oral and parenteral dosage forms, and special extemporaneous dosage forms intended for bioavailability, pharmacokinetic, and drug safety dosage studies in humans and animals.

Since 2002 Frank has provided Consulting Services and due diligence to both Big Pharma and Virtual Pharmaceutical companies. He has served as an Expert/Expert Witness in 24 US Hatch-Waxman Paragraph IV and Canadian Notice of Allegation pharmaceutical patent litigation cases for US and Canadian Pharma Companies

Dr. Chrzanowski has a BS (Pharmacy), MS and PhD (Pharmaceutics) degrees all from the Philadelphia College of Pharmacy and Science (Pharmaceutics), which is now a part of St Joseph’s University (Philadelphia).